A Critical Discussion: Possibility of the Strategic Treatment for Various Tumors Using the Leukotriene Receptor Antagonist Based on the Common Pathologic Findings that Mast Cells and Leukotrienes are Involved in the Development and Proliferation of Tumors

Abstract

The leukotriene receptor antagonist is indicated with a therapeutic drug of asthma and is one of the antiallergic agents. We found that mast cells and a leukotriene receptor commonly emerged for various malignant and benign tumors and proved that the allergic reaction was strongly associated with development and proliferation of tumors. And we experimented on the effect of treatment of the leukotriene receptor antagonist for spontaneous rat tumor and confirmed the efficacy. Our data show a wide effect of this medicine and the fewer side effects and will cause a discussion for the chemotherapy of the current malignant tumor. This commentary briefly summarizes about current evidence and future prospect in the oncotherapy of the leukotriene receptor antagonist. As a future therapy for tumors, combination therapy with leukotriene receptor antagonists alone or other drugs is expected. We also hope that preventive medicine will be developed that prevents malignant transformation of benign tumors.